Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1742.1.

https://doi.org/10.1182/blood-2024-198727

Published: 2024

Journal Articles

Uncovering Root Causes Underlying Gaps in the Evaluation and Integration of the Latest Clinical Evidence in Congenital Thrombotic Thrombocytopenic Purpura: Key Findings from a National Hematology Care Team Survey

Azra Borogovac, Ellie Moses-Okwei, Lindsay Gurska, Emily Zyborowicz, Shelby Sullivan, Jeffrey Carter, Cherilyn Heggen

Blood (2024) 144 (Supplement 1): 3636.

https://doi.org/10.1182/blood-2024-203312

Published: 2024

Journal Articles

Phase 1b Study of IDH Inhibition with Enasidenib and MEK Inhibition with Cobimetinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene Mutations

Brian J. Ball, Jianying Zhang, Michelle Afkhami, Marjorie Robbins, Lauren Chang, Samantha Humpal, Vania Porras, Yilun Liu, Tim W Synold, Sarah Farzinkhou, Azra Borogovac, Paul B. Koller, Hoda Pourhassan, Vaibhav Agrawal, Anthony S. Stein, Mary-Elizabeth M. Percival, Alexey V. Danilov, Guido Marcucci

Blood (2024) 144 (Supplement 1): 6043.

https://doi.org/10.1182/blood-2024-211652

Published: 2024

Journal Articles

A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 459.

https://doi.org/10.1182/blood-2024-204113

Published: 2024

Journal Articles

Evaluating the Impact of Hereditary Thrombotic Thrombocytopenic Purpura (hTTP) on Patients: A Patient Reported Outcomes (PROs) Study

Azra Borogovac, Honieh Sowdagar, Julia Naifeh, Marissa Schraner, Johanna A. Kremer Hovinga, Devon Mack, Sara Vesely, James N. George, Deirdra Terrell

Blood (2023) 142 (Supplement 1): 3756.

https://doi.org/10.1182/blood-2023-190338

Published: 2023

Journal Articles

Prior Immune Effector Cell Therapy, Is Not Associated with an Increased Infectious Risk of Subsequent Bispecific Antibody Therapy for Multiple Myeloma

Lawrence Liu, Scott R. Goldsmith, Sheryl Leahey, Carlos Gomez Luna, Shawn Streeter, Adam Braun, Nitya Nathwani, Michael Rosenzweig, Firoozeh Sahebi, Azra Borogovac, Jonathan Keats, Myo Htut, Arnab Chowdhury, Sanjeet Singh Dadwal, Amrita Krishnan, Murali Janakiram

Blood (2023) 142 (Supplement 1): 1987.

https://doi.org/10.1182/blood-2023-188077

Published: 2023

Journal Articles

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Blood (2022) 140 (Supplement 1): 9390–9392.

https://doi.org/10.1182/blood-2022-159001

Published: 2022

Journal Articles

Disparities in Somatic Mutations and Outcomes in Primary Central Nervous System Lymphoma Comparing Patients of Hispanic and Non-Hispanic Ethnicity

Haifaa Abdulhaq, Omar Mahmood, Calvin Kuan Jung Chen, Azra Borogovac, Matthew Wieduwilt, Anand Annan, Yueqi Yan, Maher Albitar

Blood (2022) 140 (Supplement 1): 3553–3554.

https://doi.org/10.1182/blood-2022-164902

Published: 2022

Journal Articles

Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura

Azra Borogovac, Erika Tarasco, Johanna A. Kremer Hovinga, Kenneth D. Friedman, Adam S. Asch, Sara K. Vesely, Calin I. Prodan, Deirdra R. Terrell, James N. George

Blood (2022) 140 (7): 785–789.

https://doi.org/10.1182/blood.2022016044

Published: 2022

Includes: Supplemental data

Journal Articles

Prevalence of Stroke and Cognitive Impairment in Patients with Hereditary Thrombotic Thrombocytopenic Purpura

Azra Borogovac, Erika Tarasco, Johanna A. Kremer Hovinga Strebel, Kenneth D. Friedman, Adam S. Asch, Sara K. Vesely, Calin I. Prodan, James N. George

Blood (2021) 138 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2021-148714

Published: 2021

Journal Articles

Successful Development of an Outpatient Chimeric Antigen Receptor (CAR) T Cell Therapy Program

Azra Borogovac, Amany R. Keruakous, Michelle Bycko, Jennifer Holter Chakrabarty, Sami Ibrahimi, Mohamad O. Khawandanah, George B. Selby, Carrie Yuen, Sarah A. Schmidt, Taha Al-Juhaishi, Matthew Wieduwilt, Adam S. Asch

Blood (2021) 138 (Supplement 1): 4821.

https://doi.org/10.1182/blood-2021-153457

Published: 2021

Journal Articles

Frequency and Severity of Pregnancy Complications in Women with Hereditary Thrombotic Thrombocytopenic Purpura

Rana Kasht, Azra Borogovac, MD, James N. George, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-134394

Published: 2020

Journal Articles

Recognizing Hereditary TTP in Infants and Children

Anam Siddiqui, Azra Borogovac, MD, James N. George, MD, Janna M. Journeycake, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-133918

Published: 2020

Journal Articles

Stroke and Myocardial Infarction (MI) in Hereditary Thrombotic Thrombocytopenic Purpura (HTTP): Similarities to Sickle Cell Anemia (SSA)

Azra Borogovac, MD, James George, MD

Blood (2019) 134 (Supplement_1): 1079.

https://doi.org/10.1182/blood-2019-122208

Published: 2019

NARROW

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Uncovering Root Causes Underlying Gaps in the Evaluation and Integration of the Latest Clinical Evidence in Congenital Thrombotic Thrombocytopenic Purpura: Key Findings from a National Hematology Care Team Survey

Phase 1b Study of IDH Inhibition with Enasidenib and MEK Inhibition with Cobimetinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene Mutations

A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma

Evaluating the Impact of Hereditary Thrombotic Thrombocytopenic Purpura (hTTP) on Patients: A Patient Reported Outcomes (PROs) Study

Prior Immune Effector Cell Therapy, Is Not Associated with an Increased Infectious Risk of Subsequent Bispecific Antibody Therapy for Multiple Myeloma

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Disparities in Somatic Mutations and Outcomes in Primary Central Nervous System Lymphoma Comparing Patients of Hispanic and Non-Hispanic Ethnicity

Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura

Prevalence of Stroke and Cognitive Impairment in Patients with Hereditary Thrombotic Thrombocytopenic Purpura

Successful Development of an Outpatient Chimeric Antigen Receptor (CAR) T Cell Therapy Program

Frequency and Severity of Pregnancy Complications in Women with Hereditary Thrombotic Thrombocytopenic Purpura

Recognizing Hereditary TTP in Infants and Children

Stroke and Myocardial Infarction (MI) in Hereditary Thrombotic Thrombocytopenic Purpura (HTTP): Similarities to Sickle Cell Anemia (SSA)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only